Ginkgo Bioworks Holdings, Inc. Share Price

Equities

DNA

US37611X1000

Biotechnology & Medical Research

Market Closed - Nyse 01:30:02 27/04/2024 am IST 5-day change 1st Jan Change
0.8601 USD +10.60% Intraday chart for Ginkgo Bioworks Holdings, Inc. -0.55% -49.11%
Sales 2024 * 223M 18.61B Sales 2025 * 310M 25.83B Capitalization 1.72B 144B
Net income 2024 * -631M -52.61B Net income 2025 * -534M -44.52B EV / Sales 2024 * 4.68 x
Net cash position 2024 * 676M 56.38B Net cash position 2025 * 550M 45.82B EV / Sales 2025 * 3.78 x
P/E ratio 2024 *
-2.69 x
P/E ratio 2025 *
-3.17 x
Employees 1,218
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.98%
More Fundamentals * Assessed data
Dynamic Chart
Il Granaio delle Idee and Ginkgo Bioworks Announces Strategic Collaboration to Optimize Sourdough Strains for Bakery Products CI
Transcript : Ginkgo Bioworks Holdings, Inc. Presents at Ginkgo's Annual Ferment Conference 2024, Apr-11-2024
Ginkgo Bioworks Acquires AgBiome's Platform Assets MT
Ginkgo Bioworks Expands Research Partnership With Novo Nordisk MT
Ginkgo Bioworks Partners With IdeeLab Biotechnology in Brazil MT
IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service CI
Ginkgo Bioworks, Prozomix Collaborate on Enzyme Development MT
Prozomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API Manufacturing CI
Ginkgo Bioworks (NYSE: DNA) completed the acquisition of cell therapy platform assets of Modulus Therapeutics. CI
Ginkgo Bioworks Awarded $6 Million DARPA Contract to Work on Cold-Weather Applications for Military and Commercial Use MT
Ginkgo Bioworks Wins DARPA Funding to Produce Novel Proteins to Control Ice in Extreme Cold Weather Environments CI
Ginkgo Bioworks, AQUA Cultured Foods to Support Fish-Free Seafood Production MT
AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production CI
Ginkgo Bioworks, Imagindairy to Develop Animal-Free Dairy Proteins MT
Imagindairy and Ginkgo Bioworks Collaborate to Develop and Produce Animal-Free Non-Whey Dairy Proteins CI
More news
1 day+10.60%
1 week-0.55%
Current month-25.85%
1 month-19.62%
3 months-33.33%
6 months-41.09%
Current year-49.11%
More quotes
1 week
0.74
Extreme 0.7403
0.93
1 month
0.74
Extreme 0.7403
1.20
Current year
0.74
Extreme 0.7403
1.72
1 year
0.74
Extreme 0.7403
2.55
3 years
0.74
Extreme 0.7403
15.86
5 years
0.74
Extreme 0.7403
15.86
10 years
0.74
Extreme 0.7403
15.86
More quotes
Managers TitleAgeSince
Founder - 01/08/01
Founder - 01/08/01
Founder 43 01/08/01
Members of the board TitleAgeSince
Director/Board Member 56 16/21/16
Chairman 65 16/21/16
Director/Board Member 62 02/22/02
More insiders
Date Price Change Volume
26/24/26 0.8601 +10.60% 71,222,534
25/24/25 0.7777 -8.05% 72,790,347
24/24/24 0.8458 -2.84% 45,516,704
23/24/23 0.8705 +3.29% 55,623,942
22/24/22 0.8428 -2.56% 51,997,262

Delayed Quote Nyse, April 27, 2024 at 01:30 am IST

More quotes
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
0.8601 USD
Average target price
1.92 USD
Spread / Average Target
+123.23%
Consensus